Generic Name and Formulations:
Japanese encephalitis virus vaccine; inactivated; aluminum hydroxide adsorbed; susp for IM inj; contains formaldehyde, protamine sulfate; preservative-free.
Indications for IXIARO:
Japanese encephalitis virus (JEV) immunization in patients ≥2mos of age.
Adults and Children:
<2mos: not established. Give only by IM inj into anterolateral aspect of the thigh (2mos–<3yrs) or the deltoid muscle (≥3yrs; for 1–<3yrs if muscle mass adequate). Primary series: complete series at least 1 week before potential exposure. 2mos–<3yrs: two 0.25mL doses, given 28 days apart; 3–<18yrs: two 0.5mL doses, given 28 days apart; 18–65yrs: two 0.5mL doses, given either 7 days or 28 days apart; >65yrs: two 0.5mL doses, given 28 days apart. Booster dose (3rd dose): may give at least 11mos after completing the primary series if JEV risks remain; (14mos–<3yrs): one 0.25mL dose; (≥3yrs): one 0.5mL dose.
Severe allergic reaction (eg, anaphylaxis) after a previous dose.
Immunocompromised. Allergy to protamine sulfate. Have appropriate medical treatment readily available. Pregnancy. Nursing mothers.
Japanese encephalitis vaccine.
Avoid concomitant injectable vaccines in the same syringe or injection site; see full labeling. Immunosuppressants may diminish immune response.
Inj site reactions (eg, redness, pain, tenderness), fever, irritability, diarrhea, headache, myalgia; hypersensitivity reactions, syncope.
Single-dose syringe (0.5mL)—1
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Blunted Cardiovascular Stress Reactivity in Fibromyalgia With Comorbid PTSD
- Name-Brand Medications Driving Spike in U.S. Drug Spending
- Physician Responsibility to Combat "Fake News" in Medicine
- The Future Of Robot Physicians: Is Artificial Intelligence Poised to Take Over Medicine?
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?